---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016182"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T03:51:51.901111+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial

## Summary
- BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.
- IND-enabling testing for BP1001-A expected in Q4 2024; preclinical studies ongoing.
- Discontinues Phase 1 study of BP1002 for lymphoma/CLL due to enrollment challenges.
- Company reallocates resources to metabolic program from oncology pipeline.

## SEC filing metadata
- accession: 0001558370-24-016182
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/0001558370-24-016182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/bpth-20241211x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016182
- JSON: https://secwatch.observer/filing/0001558370-24-016182.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.